AVR Overview

Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.

Wall Street analysts forecast AVR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVR is17.33 USD with a low forecast of 15.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Anteris Technologies Global Corp revenue for the last quarter amounts to 310.00K USD, decreased -42.18

Anteris Technologies Global Corp. EPS for the last quarter amounts to -0.74 USD, increased 37.04

Anteris Technologies Global Corp (AVR) has 174 emplpoyees as of March 11 2026.

Today AVR has the market capitalization of 620.34M USD.